Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb

2021 Year in Review - Biosimilars —December 30, 2021

Categories:

Biosimilars

The results of the cost-efficiency analysis within the Centers for Medicare & Medicaid Services Oncology Care Model indicate that switching from reference pegfilgrastim to pegfilgrastim-jmdb provided cost-savings that could potentially be reallocated to food and transportation support.

Using the Centers for Medicare & Medicaid Services Oncology Care Model, researchers analyzed potential cost-efficiency gains from switching selected patients with cancer from reference pegfilgrastim to its biosimilar (pegfilgrastim-jmdb) and simulated reallocating the savings gained to provide nutrition and transportation support to Centers for Medicare & Medicaid Services beneficiaries.

The Surveillance, Epidemiology, and End Results database was used to extract incidence rates for breast, ovarian, lung, and colorectal cancers and non-Hodgkin lymphoma, with stratification by age <65 years (commercial insurance) or >65 years (Medicare). It was assumed that 19.4% of chemotherapy (tumor type-matched) would require pegfilgrastim prophylaxis. Two models compared prefilled syringe and on-body injector pegfilgrastim reference to prefilled syringe pegfilgrastim-jmdb. Cost inputs included Average Sales Price 3Q20 for Medicare and National Average Drug Acquisition Cost for Medicaid patients, plus medication administration.

In 2020, it was estimated that 31,210 Medicare and 1722 Medicaid patients in the 5 tumor types required pegfilgrastim prophylaxis. Switching pegfilgrastim to pegfilgrastim-jmdb in these patients provided estimated cost-savings of up to approximately $19 million (Medicare) and approximately $20 million (Medicaid). Using simulation models, these cost-savings translated to a monthly $100 food or transportation check to at least 24,716 Medicare or 33,630 Medicaid patients for 6 months.

Based on the results of the cost-efficiency analyses, the authors concluded that switching to a biosimilar afforded cost-savings that could potentially be reallocated on a budget-neutral basis to food and transportation support.

Source: Macdonald K, Al Rawashdh N, McBride A, et al. Cost-efficiency analysis of conversion from reference pegfilgrastim to its biosimilar (pegfilgrastim-jmdb) and expanded access to food and transportation support for Medicare/Medicaid patients within the CMS Oncology Care Model. J Clin Oncol. 2021;39(suppl_15):e18837.

Related Articles
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars
The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC.
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
2021 Year in Review - Biosimilars
The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings.
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
2021 Year in Review - Biosimilars
Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country